CLINICAL EVIDENCE — PROVEN PLATFORM TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

The Evolut TAVR System Proven Platform

The EvolutTM TAVR System is built on a proven platform that provides industry-leading hemodynamics, advanced sealing and a low-profile delivery. The CoreValveTM TAVR platform is the only TAVR platform currently on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patient at 3 years.1

COREVALVE U.S. PIVOTAL HIGH RISK TRIAL2

The CoreValve U.S. Pivotal High Risk Trial is a prospective, randomized, multicenter, noninferiority trial to compare the safety and efficacy of the Medtronic CoreValve system to SAVR in patients with symptomatic severe aortic stenosis at increased surgical risk.

  • Study Status/Duration: 3-year outcomes reported/5-year follow-up
  • Sample Size: N = 795 (TAVR = 391, SAVR = 359)
  • Devices: CoreValve TAV

The Medtronic TAVR supra-annular valve design contributes to industry-leading hemodynamics.

LIFELINE CARDIOVASCULAR TECHNICAL SUPPORT

877-526-7890

rs.cstechsupport@medtronic.com

STAY

INFORMED

Receive email updates about Medtronic TAVR.

SIGN UP

MEDTRONIC

ACADEMY

View more clinical data and access procedural resources.

LOG IN OR REGISTER

1

Deeb, et al. (2015) presentation

2

Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. June 7, 2016;67(22):2565-2574.